Dr Calixto Jose Cornavaca Diaz, MD | |
578 S Enota Dr Ne, Ste C, Buford, GA 30519-4392 | |
(423) 619-8381 | |
(470) 290-8474 |
Full Name | Dr Calixto Jose Cornavaca Diaz |
---|---|
Gender | Male |
Speciality | General Practice |
Experience | 18 Years |
Location | 578 S Enota Dr Ne, Buford, Georgia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1326381625 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 74951 (Georgia) | Primary |
Entity Name | Calixto J Cornavaca Diaz Md Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1487140349 PECOS PAC ID: 2961756432 Enrollment ID: O20181120000757 |
News Archive
Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.
Vermillion, a molecular diagnostics company, today announced that it has signed an agreement with Quest Diagnostics to make OVA1 available in India. The companies are targeting a launch in the second quarter of 2011. Additionally, at the International Gynecologic Cancer Society (IGCS) regional meeting held in New Delhi April 2-3, 2011, Dr. Fred Ueland presented data demonstrating the high sensitivity for ovarian malignancy of OVA1 in combination with ultrasound.
Prominent journalists including the late Pulitzer Prize-winner Charles Krauthammer, have written that doctors are leaving the practice of medicine because adopting and using electronic health records is frustrating and debilitating.
Scientists from Freie Universität Berlin and the NeuroCure Cluster of Excellence led by biochemist Volker Haucke in collaboration with colleagues from Australia and the Leibniz Institute for Molecular Pharmacology in Berlin have developed small molecules that inhibit the internalization of important signaling molecules but also of pathogenic organisms such as the immunodeficiency virus and bacteria into cells.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Calixto Jose Cornavaca Diaz, MD 578 S Enota Dr Ne Ste C, Gainesville, GA 30501-8947 Ph: (470) 892-6607 | Dr Calixto Jose Cornavaca Diaz, MD 578 S Enota Dr Ne, Ste C, Buford, GA 30519-4392 Ph: (423) 619-8381 |
News Archive
Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.
Vermillion, a molecular diagnostics company, today announced that it has signed an agreement with Quest Diagnostics to make OVA1 available in India. The companies are targeting a launch in the second quarter of 2011. Additionally, at the International Gynecologic Cancer Society (IGCS) regional meeting held in New Delhi April 2-3, 2011, Dr. Fred Ueland presented data demonstrating the high sensitivity for ovarian malignancy of OVA1 in combination with ultrasound.
Prominent journalists including the late Pulitzer Prize-winner Charles Krauthammer, have written that doctors are leaving the practice of medicine because adopting and using electronic health records is frustrating and debilitating.
Scientists from Freie Universität Berlin and the NeuroCure Cluster of Excellence led by biochemist Volker Haucke in collaboration with colleagues from Australia and the Leibniz Institute for Molecular Pharmacology in Berlin have developed small molecules that inhibit the internalization of important signaling molecules but also of pathogenic organisms such as the immunodeficiency virus and bacteria into cells.
› Verified 3 days ago
Dr. Hazim A Farisi, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 4965 Friendship Rd, St 103, Buford, GA 30518 Phone: 678-714-5692 Fax: 678-714-5693 |